Viva Biotech Holdings (1873.HK) enables small molecule and biologics drug discovery with leading position in structural biology and biophysics. Our service areas include protein expression and structure research, medicinal chemistry, hit screening, bioassays, membrane protein, antibody discovery, engineering & drug candidate determination. Differentiating technologies include X-Ray crystallization, ASMS, SPR, SBDD, FBDD, GPCR, Fab/Ag Co-Crystal.
Viva BioInnovator (“VBI”) is the investment division of Viva Biotech Holdings. We primarily focus on innovative therapeutic companies in all disease areas. Our seed to A-round funding is typically in the range of $0.5M – $5M. We have invested in over 40 companies worldwide, and plan to add more than 30 startup companies into our portfolio in 2020.
Our mission is to become a cradle for promising biotechnology startups around the world.